scholarly journals L-Glutamine and Whole Protein Restore First-Phase Insulin Response and Increase Glucagon-Like Peptide-1 in Type 2 Diabetes Patients

Nutrients ◽  
2015 ◽  
Vol 7 (4) ◽  
pp. 2101-2108 ◽  
Author(s):  
Dorit Samocha-Bonet ◽  
Don Chisholm ◽  
Jens Holst ◽  
Jerry Greenfield
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Response ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
First Phase Insulin Response ◽  
Diabetes Patients

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early Type 2 diabetes

1998 ◽  
Vol 95 (3) ◽  
pp. 325-329 ◽  
Author(s):  
Jeannie F. TODD ◽  
C. Mark B. EDWARDS ◽  
Mohammad A. GHATEI ◽  
Hugh M. MATHER ◽  
Stephen R. BLOOM
Keyword(s):  
Type 2 Diabetes ◽  
Glycaemic Control ◽  
Plasma Glucose ◽  
Test Meal ◽  
Insulin Response ◽  
Standard Test ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
First Phase Insulin Response

1.Glucagon-like peptide-1 (7-36) amide (GLP-1) is released into the circulation after meals and is the most potent physiological insulinotropic hormone in man. GLP-1 has the advantages over other therapeutic agents for Type 2 diabetes of also suppressing glucagon secretion and delaying gastric emptying. One of the initial abnormalities of Type 2 diabetes is the loss of the first-phase insulin response, leading to postprandial hyperglycaemia. 2.To investigate the therapeutic potential of GLP-1 in Type 2 diabetes, six patients were entered into a 6-week, double-blind crossover trial during which each received 3 weeks treatment with subcutaneous GLP-1 or saline, self-administered three times a day immediately before meals. A standard test meal was given at the beginning and end of each treatment period. 3.GLP-1 reduced plasma glucose area under the curve (AUC) after the standard test meal by 58% (AUC, 0–240 ;min: GLP-1 start of treatment, 196±141 ;mmol·min-1·l-1; saline start of treatment, 469±124 ;mmol·min-1·l-1; F = 16.4, P< 0.05). The plasma insulin excursions were significantly higher with GLP-1 compared with saline over the initial postprandial 30 ;min, the time period during which the GLP-1 concentration was considerably elevated. The plasma glucagon levels were significantly lower over the 240-min postprandial period with GLP-1 treatment. The beneficial effects of GLP-1 on plasma glucose, insulin and glucagon concentrations were fully maintained for the 3-week treatment period. 4.We have demonstrated a significant improvement in postprandial glycaemic control with subcutaneous GLP-1 treatment. GLP-1 improves glycaemic control partially by restoring the first-phase insulin response and suppressing glucagon and is a potential treatment for Type 2 diabetes.

scholarly journals Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients

2016 ◽  
Vol 101 (5) ◽  
pp. 2122-2129 ◽  
Author(s):  
Jennifer S. ten Kulve ◽  
Liselotte van Bloemendaal ◽  
Rawien Balesar ◽  
Richard G. IJzerman ◽  
Dick F. Swaab ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Expression ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Diabetes Patients

scholarly journals Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

2010 ◽  
Vol 1 (1-2) ◽  
pp. 56-59 ◽  
Author(s):  
Daisuke Yabe ◽  
Akira Kuroe ◽  
Soushou Lee ◽  
Koin Watanabe ◽  
Takanori Hyo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Healthy Controls ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Diabetes Patients

scholarly journals Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries

2014 ◽  
Vol 5 (2) ◽  
pp. 499-520 ◽  
Author(s):  
Victoria Divino ◽  
Mitch DeKoven ◽  
Shawn Hallinan ◽  
Nebibe Varol ◽  
Sara Bruce Wirta ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Treatment Patterns ◽  
European Countries ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Diabetes Patients

scholarly journals Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e50117 ◽  
Author(s):  
Daniel J. Cuthbertson ◽  
Andrew Irwin ◽  
Chris J. Gardner ◽  
Christina Daousi ◽  
Tej Purewal ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Fat ◽  
Receptor Agonists ◽  
Fat Reduction ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Diabetes Patients
Sign in / Sign up

Export Citation Format

Share Document